Mobile After-Care Support Intervention for Patients With Schizophrenia Following Hospitalization: Pilot RCT
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Psychotic Disorder
- Sponsor
- Butler Hospital
- Enrollment
- 42
- Locations
- 1
- Primary Endpoint
- Client Satisfaction Questionnaire (CSQ)
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The overall aim of this program of research is to refine and test the feasibility and acceptability of a newly developed mobile device-delivered app, called Mobile After-Care Support (MACS), to improve patients' coping and treatment adherence following a hospitalization related to their psychotic-spectrum disorder. The purpose of the proposed project is to establish the feasibility, acceptability, and preliminary effects of the app. To achieve the specific aims, the investigators will conduct a pilot randomized clinical trial (n = 60), with two treatment arms: MACS vs. a mobile app attention control condition.
Investigators
Eligibility Criteria
Inclusion Criteria
- •recently hospitalized
- •DSM-5 criteria for psychotic-spectrum disorder based on structured clinical interview
- •18 years or older
- •prescribed antipsychotic medication upon discharge
- •ability to speak and read English
Exclusion Criteria
- •substance use disorders at severe level
- •planned discharge to supervised living setting or participation in formal outpatient adherence programs
- •pregnancy or other medical condition contraindicating use of antipsychotic medications
Outcomes
Primary Outcomes
Client Satisfaction Questionnaire (CSQ)
Time Frame: 1 month
The Client Satisfaction Questionnaire is a self-report measure of patient satisfaction with treatment. The total score (sum of items) will be used and ranges from 8 to 32 with increased scores indicating greater satisfaction with treatment.
Secondary Outcomes
- Brief Adherence Rating Scale (BARS)(Baseline, 4 month)
- Brief Psychiatric Rating Scale (BPRS)(Baseline, 4 month)
- Brief Cope Inventory (Brief COPE)(Baseline, 4 month)